News for Myovant Sciences Stock (MYOV)

Myovant Reports Data, And Other News: The Good, Bad And Ugly Of Biopharma

Seeking Alpha • 09/21/20

Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program and from Prospective Observational Study

GlobeNewsWire • 09/14/20

Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids

GlobeNewsWire • 08/17/20

Myovant Sciences Announces Corporate Updates and Financial Results for First Quarter Fiscal Year 2020

GlobeNewsWire • 08/11/20

Myovant Sciences Has Limited Downside At Its Current Price

Seeking Alpha • 08/04/20

Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition Study

GlobeNewsWire • 07/06/20

BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences Launch Forward Momentum Coalition to Increase Diversity in Research and Develop New Digital Resources for Men with Prostate Cancer

GlobeNewsWire • 06/30/20

Myovant's Endometriosis Pain Drug Meets Goal in Study, Stock Up

Zacks Investment Research • 06/24/20

How This Highly Rated Biotech Stock Could Take On AbbVie, Neurocrine

Investors Business Daily • 06/23/20

Myovant's stock gains on promising endometriosis drug trial

Market Watch • 06/23/20

Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis

GlobeNewsWire • 06/23/20

Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer

GlobeNewsWire • 06/22/20

Myovant Eyes Relugolix Combo Approval for Uterine Fibroids

Zacks Investment Research • 06/02/20

Do Options Traders Know Something About Myovant (MYOV) Stock We Don't?

Zacks Investment Research • 06/02/20

Sumitovant Biopharma Announces Myovant Sciences' Submission of New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids

PRNewsWire • 06/01/20

Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids

GlobeNewsWire • 06/01/20

Sumitovant Biopharma Announces Myovant Sciences' Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine

PRNewsWire • 05/29/20

Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine

GlobeNewsWire • 05/29/20

Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2020

GlobeNewsWire • 05/18/20

Myovant Sciences to Present New Data on Relugolix in Prostate Cancer at American Society of Clinical Oncology (ASCO) 2020 Annual Meeting

GlobeNewsWire • 05/14/20

Notable Insider Buys This Past Week: Immunomedics, Simply Good Foods And More

Benzinga • 05/02/20

Myovant Sciences Announces Publication of Abstracts Detailing Additional Efficacy and Safety Findings from Phase 3 LIBERTY Studies in Uterine Fibroids in Obstetrics & Gynecology

GlobeNewsWire • 04/27/20

Myovant Squares Off with AbbVie On Endometriosis Treatment

The Motley Fool • 04/26/20

Myovant Eyes Relugolix Approval for Advanced Prostate Cancer

Zacks Investment Research • 04/22/20

Myovant Sciences Announces Positive Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study

GlobeNewsWire • 04/22/20